Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement […]
Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC) […]
Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production […]
Heidelberg Pharma signs Option Agreement with Max Delbrück Center […]
European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin […]
Advanced Proteome Therapeutics Corporation and Heidelberg Pharma collaborate to create improved cancer therapeutics […]
WILEX AG today announced that Professor Andreas Pahl has been appointed to the company’s Executive Management Board to serve as the new Head of Research and Development […]
US-patent office granted patent for amatoxin conjugates for tumour therapy […]
WILEX AG announces discontinuation of collaboration between its subsidiary Heidelberg Pharma and Roche […]
Results of Heidelberg Pharma’s research cooperation with M.D. Anderson Cancer Center published in Nature journal […]
Heidelberg Pharma, a wholly owned subsidiary of WILEX AG, has been awarded a research grant from the European Union as part of the European Training Network (ETN) MAGICBULLET […]
Heidelberg Pharma, a wholly owned subsidiary of WILEX AG, receives research grant for development of PSMA antibody drug conjugates […]
Heidelberg Pharma, a wholly owned subsidiary of WILEX AG, extends research collaboration with Roche […]
Heidelberg Pharma is very pleased to invite you to a Taconic Webinar on »Human TNF-α Transgenic Mouse Model of Spontaneous Arthritis« presented by our CSO, Prof. Dr. Andreas Pahl.
Audiorecording and presentation slides are available at Taconic’s website or at this website.
Heidelberg Pharma, a wholly owned subsidiary of WILEX AG, signs license agreement for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche […]
Heidelberg Pharma has relaunched its website Heidelberg Pharma to provide visitors with a clear understanding of the pre-clincal services offered by Heidelberg Pharma. The new website includes more in-depth information about Heidelberg Pharma’s ADC technology.